» Articles » PMID: 29574715

Treatment and Outcome of Adult-onset Neuroblastoma

Overview
Journal Int J Cancer
Specialty Oncology
Date 2018 Mar 26
PMID 29574715
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Adult-onset neuroblastoma is rare and little is known about its biology and clinical course. There is no established therapy for adult-onset neuroblastoma. Anti-GD2 immunotherapy is now standard therapy in children with high-risk neuroblastoma; however, its use has not been reported in adults. Forty-four adults (18-71 years old) diagnosed with neuroblastoma between 1979 and 2015 were treated at Memorial Sloan Kettering Cancer Center. Five, 1, 5 and 33 patients had INSS stage 1, 2, 3 and 4 diseases, respectively. Genetic abnormalities included somatic ATRX (58%) and ALK mutations (42%) but not MYCN-amplification. In the 11 patients with locoregional disease, 10-year progression-free (PFS) and overall survival (OS) was 35.4 ± 16.1% and 61.4 ± 15.3%, respectively. Among 33 adults with stage 4 neuroblastoma, 7 (21%) achieved complete response (CR) after induction chemotherapy and/or surgery. Seven patients with primary refractory neuroblastoma (all with osteomedullary but no soft tissue disease) received anti-GD2 antibodies, mouse or humanized 3F8. Antibody-related adverse events were similar to those in children, response rate being 71.4%. In patients with stage 4 disease at diagnosis, 5-year PFS was 9.7± 5.3% and most patients who were alive with disease at 5 years died of neuroblastoma over the next 5 years, 10-year OS being only 19.0 ± 8.2%. Patients who achieved CR after induction had superior PFS and OS (p = 0.006, p = 0.031, respectively). Adult-onset neuroblastoma appeared to have different biology from pediatric or adolescent NB, and poorer outcome. Complete disease control appeared to improve long-term survival. Anti-GD2 immunotherapy was well tolerated and might be beneficial.

Citing Articles

Adult-onset pancreatic neuroblastoma: A case report with a literature review.

Alshadood N, Aldarawsha A, Al-Badri S, Elazab M, Mahdi M, Yousif F Radiol Case Rep. 2024; 20(1):539-544.

PMID: 39559503 PMC: 11570904. DOI: 10.1016/j.radcr.2024.10.066.


Metanephrine mirage: distinguishing the phaeocopies, a case report and literature review.

Gong J, Gordon D, Ye S, Fleming B, Tan J, Hulf T Clin Diabetes Endocrinol. 2024; 10(1):37.

PMID: 39548528 PMC: 11568592. DOI: 10.1186/s40842-024-00198-1.


An Unusual Occurrence of Metastases to Multiple Muscles in Neuroblastoma.

Khan D, Sagar S, Shamim S, Kaushik P, Kumar R Indian J Nucl Med. 2024; 39(3):222-223.

PMID: 39291061 PMC: 11404728. DOI: 10.4103/ijnm.ijnm_37_23.


Anterior mediastinal neuroblastoma in an adult: an additional case of a rare tumor in an unusual location with review of the literature.

Collins K, Ulbright T, Davis J Diagn Pathol. 2023; 18(1):127.

PMID: 38031161 PMC: 10685643. DOI: 10.1186/s13000-023-01417-6.


Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.

Stiefel J, Kushner B, Roberts S, Iglesias-Cardenas F, Kramer K, Modak S JCO Precis Oncol. 2023; 7:e2300138.

PMID: 37561984 PMC: 10581627. DOI: 10.1200/PO.23.00138.


References
1.
Dosik G, Rodriguez V, Benjamin R, Bodey G . Neuroblastoma in the adult: effective combination chemotherapy. Cancer. 1978; 41(1):56-63. DOI: 10.1002/1097-0142(197801)41:1<56::aid-cncr2820410110>3.0.co;2-2. View

2.
Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

3.
Roberts S, Chou A, Cheung N . Immunotherapy of Childhood Sarcomas. Front Oncol. 2015; 5:181. PMC: 4528283. DOI: 10.3389/fonc.2015.00181. View

4.
Lopez R, Karakousis C, Rao U . Treatment of adult neuroblastoma. Cancer. 1980; 45(5):840-4. DOI: 10.1002/1097-0142(19800301)45:5<840::aid-cncr2820450503>3.0.co;2-z. View

5.
He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J . Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children. Transl Oncol. 2017; 10(6):936-941. PMC: 5704095. DOI: 10.1016/j.tranon.2017.09.008. View